Answers are grounded in this paper and cite their sources.
The updated 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines proposed revised scoring for both immunohistochemical (IHC)– and in situ hybridization–determined HER2 status with the aim of capturing all patients with breast cancer eligible for targeted therapy.1 The new guidelines also increased the number of patients classified as having equivocal IHC, resulting in more cases requiring reflex fluorescence in situ hybridization (FISH) testing. The current guidelines also address intratumoral heterogeneity using immunohistochemistry as a platform to identify and target heterogeneously staining “hot-spot” areas forFISH analysis.2 Clinical significance of HER2 heterogeneity remains unclear. However, benefits of HER2-targeted therapy in patients with 10% to 30% intense membrane staining by IHC and HER2:CEP17 ratios between 2 and 2.2, as determined by dual-probe FISH assays (both classified as “equivocal” following older 2007 ASCO/CAP guidelines), are documented.3In our national reference laboratory, we offer HER2 testing as IHC or FISH only and also as a reflex FISH following equivocal (2+) IHC. Both IHC interpretation and FISH scoring are done by pathologists. After implementation of the ASCO/CAP 2013 guidelines, we are marking the areas of most-intense membrane staining in cases in which IHC staining is equivocal (2+) with weak or moderate staining within more than 10%, or complete, intense membrane staining within less than 10% of the invasive tumor cells. Reflex dual-probe FISH testing is then performed by scanning the whole slide and scoring the previously circled areas (“IHC2+/reflex FISH” group). In those cases in which samples are received for FISH testing only, the pathologist circles the entire area of invasive tumor on hematoxylin-eosin slides, and FISH scoring is performed without preferentially scoring a predetermined area (“FISH only” group). Amplification rates between the IHC2+/reflex FISH group with targeted areas for FISH and the FISH-only group in which the entire invasive carcinoma was marked on hematoxylin-eosin slide were similar (16.3% and 20%, respectively) (P = .06); 10 of 595 IHC2+/reflex FISH (1.7%) and 15 of 1210 FISH-only (1.2%) groups showed genetic heterogeneity by FISH with discrete population of amplified tumor cells comprising >10% respectively (P = .40). Detection of intratumoral heterogeneity by HER2 IHC does not yield to identification of HER2-amplified cases or breast cancer with genetic heterogeneity by in situ hybridization following 2013 ACSO/CAP guidelines.
No takes yet. Share an insight, caveat, or question.
Gulbahce et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: